2/20/2009

CuraGen is looking at "strategic alternatives," including putting itself up for sale, to "enhance shareholder value," said Robert E. Patricelli, the biotech firm's board chairman. The Branford, Conn., company is also considering selling or licensing CR011, its cancer-drug candidate.

Related Summaries